

Completion Of RHYO Option Underwriting

Highlights

- ✓ Completion of successful exercise and underwriting of \$5.5m of RHYO options.
- ✓ Validation of ongoing support of Rhythm by existing option holders.
- ✓ The Company is now well funded to accelerate sales of ColoSTAT[®] and geneType[™].
- ✓ Rhythm has made significant progress in its transformation to a commercial organisation.

Melbourne, Australia, 14th April 2026: Rhythm Biosciences Ltd ("RHY", the "Company" or the "Group") (ASX: RHY), a transformative, predictive cancer diagnostics technology company, is pleased to advise that the underwriting by CPS Capital Group Pty Ltd ("CPS", the "Underwriter") of RHYO options expiring on 31 March 2026 as announced on 25 and 27 February, 30 and 31 March 2026, has been successfully completed.

Proceeds

\$5.5 million before costs was raised through the combination of ~\$1.7 million in option holder exercises and ~\$3.8 million in underwriting, providing additional working capital to support the Company's commercial activities designed to drive sales of ColoSTAT[®] and geneType[™] in both domestic and international markets.

Shortfall Shares and Underwriter Options

The underwritten component represents 18,834,007 new fully paid ordinary shares ("Shortfall Shares") and 3,000,000 Underwriter Options and 9,166,667 Underwriting Agreement Options to be issued to CPS and its nominees pursuant to the Underwriting Agreement.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

Directors

Gavin Fox-Smith
Sue MacLeman
David Atkins

Non-Executive Chairman
Non-Executive Director
CEO & Managing Director

www.rhythmbio.com

T +61 3 8256 2880
E info@rhythmbio.com

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT® Test is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT® Test is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.